Philip S. Tabbiner

PHILIP S. TABBINER is President and Chief Operating Officer of
aaiPharma. As President and COO, Dr. Tabbiner directs key areas
of aaiPharma’s pharmaceuticals business, including the commercial
business, NeoSan Pharmaceuticals; the research, licensing and
product development business, aaiResearch; and the corporate
administrative functions of legal, regulatory affairs, quality
assurance and corporate communications. Dr. Tabbiner joined
aaiPharma in 2000 as President of NeoSan Pharmaceuticals. Dr.
Tabbiner is a veteran of the pharmaceutical and healthcare
industry whose career has included executive positions at Bayer
Corporation, Chiron Corporation and DuPont Merck Pharmaceuticals.
Dr. Tabbiner spent nearly 20 years with DuPont Merck with
responsibilities spanning from overseeing the Canadian operations
of the pharmaceuticals business, running the original generics
business, and directing North American marketing for the
pharmaceuticals business to leading worldwide sales and marketing
for the Radiopharmaceuticals Division. After leaving DuPont
Merck, Dr. Tabbiner joined Chiron as President of International
and, when Bayer acquired Chiron, he moved on to Bayer Diagnostics
to lead the business development, strategic planning and
marketing aspects of the business. Dr. Tabbiner has his doctorate
in Business Administration, an MBA in Strategic Management and a
Bachelor’s Degree in Economics. He has held numerous positions in
industry organizations and business councils.